Progress of Clinical Research on Trop2 in Solid Tumors

Trophoblast cell surface antigen 2 (Trop2) is a glycoprotein that is barely expressed in normal tissues but highly expressed in malignant tumors; it is remarkably associated with poor prognosis. Various targeted therapeutics against Trop2, such as anti-Trop2 antibodies and antibody-drug conjugate dr...

Full description

Saved in:
Bibliographic Details
Published inZhongliu fangzhi yanjiu Vol. 52; no. 1; pp. 79 - 86
Main Authors Zhang, Ying, Liu, Yueping
Format Journal Article
LanguageChinese
English
Published Tianjin China Anti-Cancer Association 01.01.2025
Magazine House of Cancer Research on Prevention and Treatment
Subjects
Antibodies
cancer
Cancer therapies
Cell surface
Clinical trials
Drug delivery
Drug development
Drugs
Glycoproteins
mechanism
Solid tumors
structure
targeted therapy
trop2
Tumors
Online AccessGet full text

Cover

More Information
Summary:Trophoblast cell surface antigen 2 (Trop2) is a glycoprotein that is barely expressed in normal tissues but highly expressed in malignant tumors; it is remarkably associated with poor prognosis. Various targeted therapeutics against Trop2, such as anti-Trop2 antibodies and antibody-drug conjugate drugs targeting Trop2, have been developed, and some therapeutics have been approved or are in clinical trials for cancer treatment. In this review, we comprehensively discuss the gene structure, mechanism of action, clinical research, drug development, and other aspects of Trop2 to provide references for the clinical development of effective and safe Trop2-targeting drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1000-8578
DOI:10.3971/j.issn.1000-8578.2025.24.0542